Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
bullish
PYC Therapeutics
Watchlist
PYC Therapeutics Limited - Net Positive VP-001 Update at APVRS
Equity Bottom-Up
175 Views
02 Dec 2024 23:24
Broker
Given our confidence on the safety profile of VP-001 we maintain our price target of $2.40 (VP-001 $0.90, ADPKD $0.90, ADOA $0.40 and PMS $0.20).
What is covered in the Full Insight:
Introduction to VP-001 and RP11
Phase I/II Dataset Update
Analysis of LLVA and Microperimetry Data
Upcoming Clinical Trial Design and FDA Meeting
Forecasts, Valuation, and Investment Recommendation
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 27-minute read)
Related Insights
More »
Loading
Trending Collections
More »
Loading
Trending Insights
More »
Inconsistently Dovish Pricing
[Japan Buybacks] - Japan Bank Metrics, Cross-Holdings and Banks Part 1
[Quiddity Index] TOPIX July 2025 FFW Rebalance - $3bn+ a Side to Trade
NTT DC REIT IPO: Global Index Inclusions Later This Year + A Kicker
Great Eastern (GE SP): SGX The Winner As Shareholders Block Exit Offer
Top Unpaywalled Insights
More »
Loading
Discussions
(Paid Plans Only)
Price Chart
(Sign Up to Access)
Insight Stream
PYC Therapeutics Limited - Net Positive VP-001 Update at APVRS
02 Dec 2024
Top
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.9
x